Limits...
Non-invasive proteomics-thinking about personalized breast cancer screening and treatment.

Debald M, Wolfgarten M, Walgenbach-Brünagel G, Kuhn W, Braun M - EPMA J (2010)

Bottom Line: Established screening programs have an unfavorable connotation due to significant rates of false negative as well as false positive results leading to overdiagnosis and overtherapy.The combination of a non-invasive breast-cancer-suspectability-biomarker with established clinical diagnostics could help to increase the acceptance of population based breast cancer screening programs by creating an individual risk profile, which is irrespective of mammography quality and interpretation.A simple, robust and inexpensive, non-invasive test for screening and diagnosis could easily be performed in every medical practice leading to an affordable, high-throughput instrument.

View Article: PubMed Central - PubMed

Affiliation: Department of Obstetrics and Gynecology, Center for Integrated Oncology, University of Bonn, Sigmund-Freud-Str. 25, 53105 Bonn, Germany.

ABSTRACT
The early diagnosis of breast cancer in potentially curable stages improves prognosis and consecutively reduces mortality of breast cancer patients. Established screening programs have an unfavorable connotation due to significant rates of false negative as well as false positive results leading to overdiagnosis and overtherapy. The combination of a non-invasive breast-cancer-suspectability-biomarker with established clinical diagnostics could help to increase the acceptance of population based breast cancer screening programs by creating an individual risk profile, which is irrespective of mammography quality and interpretation. Recently, non-invasive proteomic biomarkers obtained from blood, saliva or nipple aspiration fluid have been extensively investigated and might play a future role in the personalized management of breast cancer screening. A simple, robust and inexpensive, non-invasive test for screening and diagnosis could easily be performed in every medical practice leading to an affordable, high-throughput instrument. This review describes recently investigated proteomic screening biomarkers that could improve the early diagnosis of breast cancer in the following years.

No MeSH data available.


Related in: MedlinePlus

Flow-chart: Personalized Screening for breast cancer using a screening biomarker as gatekeeper before further clinical diagnostics
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3405342&req=5

Fig5: Flow-chart: Personalized Screening for breast cancer using a screening biomarker as gatekeeper before further clinical diagnostics

Mentions: Thus it is necessary to implement a reliable non-invasive test as a gatekeeper for further diagnostics among asymptomatic patients (Fig. 5). In a second step only patients with a positive breast-cancer-suspectability-biomarker would receive further imaging or biopsy. Asymptomatic patients showing a negative breast-cancer-suspectability-biomarker are not in need of additional clinical diagnostics and are spared uncertainties and anxiety due to ambiguous imaging results. Table 1 summarizes candidate non-invasive proteomic biomarkers that could improve the early diagnosis of breast cancer in the following years.Fig. 5


Non-invasive proteomics-thinking about personalized breast cancer screening and treatment.

Debald M, Wolfgarten M, Walgenbach-Brünagel G, Kuhn W, Braun M - EPMA J (2010)

Flow-chart: Personalized Screening for breast cancer using a screening biomarker as gatekeeper before further clinical diagnostics
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3405342&req=5

Fig5: Flow-chart: Personalized Screening for breast cancer using a screening biomarker as gatekeeper before further clinical diagnostics
Mentions: Thus it is necessary to implement a reliable non-invasive test as a gatekeeper for further diagnostics among asymptomatic patients (Fig. 5). In a second step only patients with a positive breast-cancer-suspectability-biomarker would receive further imaging or biopsy. Asymptomatic patients showing a negative breast-cancer-suspectability-biomarker are not in need of additional clinical diagnostics and are spared uncertainties and anxiety due to ambiguous imaging results. Table 1 summarizes candidate non-invasive proteomic biomarkers that could improve the early diagnosis of breast cancer in the following years.Fig. 5

Bottom Line: Established screening programs have an unfavorable connotation due to significant rates of false negative as well as false positive results leading to overdiagnosis and overtherapy.The combination of a non-invasive breast-cancer-suspectability-biomarker with established clinical diagnostics could help to increase the acceptance of population based breast cancer screening programs by creating an individual risk profile, which is irrespective of mammography quality and interpretation.A simple, robust and inexpensive, non-invasive test for screening and diagnosis could easily be performed in every medical practice leading to an affordable, high-throughput instrument.

View Article: PubMed Central - PubMed

Affiliation: Department of Obstetrics and Gynecology, Center for Integrated Oncology, University of Bonn, Sigmund-Freud-Str. 25, 53105 Bonn, Germany.

ABSTRACT
The early diagnosis of breast cancer in potentially curable stages improves prognosis and consecutively reduces mortality of breast cancer patients. Established screening programs have an unfavorable connotation due to significant rates of false negative as well as false positive results leading to overdiagnosis and overtherapy. The combination of a non-invasive breast-cancer-suspectability-biomarker with established clinical diagnostics could help to increase the acceptance of population based breast cancer screening programs by creating an individual risk profile, which is irrespective of mammography quality and interpretation. Recently, non-invasive proteomic biomarkers obtained from blood, saliva or nipple aspiration fluid have been extensively investigated and might play a future role in the personalized management of breast cancer screening. A simple, robust and inexpensive, non-invasive test for screening and diagnosis could easily be performed in every medical practice leading to an affordable, high-throughput instrument. This review describes recently investigated proteomic screening biomarkers that could improve the early diagnosis of breast cancer in the following years.

No MeSH data available.


Related in: MedlinePlus